ArticleAbdominal radiology (New York)2026
Computed tomography-guided radiofrequency ablation of pheochromocytomas in a small case series with von Hippel-Lindau disease: treatment safety and outcomes.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to retrospectively assess the safety and outcomes of percutaneous radiofrequency ablation (RFA) of pheochromocytomas in patients with von Hippel-Lindau disease (VHLD). MATERIALS AND
methodsBetween September 2012 and February 2025, eight pheochromocytomas (median, 15.7 mm; range, 5.5-22.5 mm) in six patients with VHLD (sex ratio = 3:3; median, 30.5 years; range, 19-48 years) were treated in eight computed tomography (CT)-guided RFA sessions. Four patients with six pheochromocytomas had undergone total or partial adrenalectomy, whereas two with two pheochromocytomas had not. No patients had pre-existing hypertension, palpitations, or sweating. Premedication was administered before the two sessions. Treatment outcomes, hypertensive crises, and other complications were assessed. Follow-up period ranged from 1 to 134 (median, 60.5) months. Wilcoxon matched-pairs signed-rank test was used for statistical analysis.
resultsOf the eight pheochromocytomas, seven were completely ablated in one session, and no local tumor progression or recurrence was observed during follow-up. Only one patient had a residual tumor when a low tube current (30 mAs) was used. Of the eight RFA sessions, five resulted in elevated blood pressure during the RFA cycles (p = 0.0078). Hypertensive crises were managed well with intravenous antihypertensive medication without complications. No patient experienced adrenal insufficiency or other major complications. A small amount of bleeding was detected around the pheochromocytomas in all sessions but did not require transfusion or intervention.
conclusionCT-guided RFA can safely treat pheochromocytomas in patients with VHLD. Hypertensive crises are frequent but well controlled. It may achieve good oncological outcomes and preserve adrenal function.
Indexed as
Identifiers
41134366What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.